Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: smh who wrote (610)	12/20/2000 10:54:13 AM
From: nigel bates	Read Replies (1) \| Respond to of 675

Time to set up a new thread (or is everyone selling...) ? ANDOVER, United Kingdom, Dec. 20 /PRNewswire/ -- Shire Pharmaceuticals Group plc (Nasdaq: SHPGY; London: SHP.L) today announces that it has signed a research, development and licensing agreement with CeNes Pharmaceuticals plc (London: CEN.L) for the development of CeNeS' dopamine D1 agonist program for the treatment of Parkinson's disease. Shire will make milestone payments and pay CeNeS royalties on products developed under the agreement. Shire has also made an equity investment in CeNeS of 500,000 pounds sterling at a price of 62 pence per share and will fund all development work. Depending on the achievement of future milestones, Shire may subscribe for a further 500,000 pound sterling of CeNeS ordinary shares at the then current market price.